Bowman Cox

Executive Editor, Manufacturing

Washington, DC

Bowman Cox leads Citeline's coverage of pharmaceutical manufacturing. He writes and edits articles on the challenges and opportunities that developments in science, technology and regulatory policy pose to manufacturers and their quality organizations. Bowman has followed various energy, environmental and health care sectors, writing news for pharmacists, chemists, engineers, lawyers and other professionals. He has moderated and presented at industry and journalism conferences, and has a background in product development, having helped launch publications, conferences and a journalism association. Bowman has a passion for connecting with professional communities, discovering their truths, telling their stories and helping them learn from each other.

Latest from Bowman Cox

Biden Launches Effort To Strengthen US Pharmaceutical Supply Chain

A fresh executive order from US president Joe Biden calls for short-term and long-term study, broad consultation, and co-ordination with allies on the domestic supply chain.

‘Shadow’ Factory Challenges Continue For US FDA

Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.

US FDA, USP Raise Questions About Valisure’s Assertions Of Benzoyl Peroxide’s Benzene Risks

The US drug regulatory authority and standard-setting organization are evaluating the drug-screening venture’s findings regarding stability and potential carcinogenic risks associated with the widely used acne treatment, which includes Rx formulations.

US FDA Seeks More Power To Confront ‘Shadow’ Factory Challenges

Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find manufacturer of contaminated eye drops that disappeared.

US FDA Pharmaceutical Quality Operations Chief Outlines Paths To Quicker Inspections

As US pharmaceutical inspectorate advances toward pre-pandemic inspection cadence, there's new focus on accelerating site inspection process, as well as effort to improve retention with quicker, more targeted training. OPQO chief Alonza Cruse reviews key ideas at GMP conference.

US FDA, USP Raise Questions About Valisure’s Assertions Of Benzoyl Peroxide’s Benzene Risks

The US drug regulatory authority and standard-setting organization are evaluating the drug-screening venture’s findings regarding stability and potential carcinogenic risks associated with the widely used acne treatment, which includes Rx formulations.